2-(4-chloro-2-methylphenoxy)propionic acid NEW

Zhejiang Kinso Pharmaceuticals Co., LTD. ("KinsoPharma") was established in December 2002, specializing in the production of fine chemicals such as API and pharmaceutical intermediates. In 2008, KinsoPharma passed the ISO9001 quality system and ISO14001 environmental management system certification respectively. And in April 2020, our company was reorganized as Zhejiang Kinso Pharmaceuticals Co., LTD. In September 2021, our factory moved to Ningxia Province. We specialize in the R&D and production of pharmaceutical APIs and intermediates, while our core R&D team has more than 20 years of pharmaceutical R&D experience. Under the support of a good R&D environment and a professional technical team, our company has obtained rich experience and outstanding achievements of new drugs and generic drugs projects. On the one hand, we focus on the R&D and production process optimization of antiviral, antimalarial and other generic drugs. On the other hand, we are also committed to the cooperative development of innovative drugs in the fields of respiratory system, hypoglycemic, etc. We are able to provide technical support to drug manufacturers and distributors in all key aspects of drug development. We insist on the principle of striving for excellence in quality management, adhere to the principle that integrity creates quality and innovation leads a bright future. Taking market as orientation, the research strength of universities and colleges as supports and continuous innovation as the driving force, our company carries out targeted technological research and innovation in the pharmaceutical field and gives full play to the transformation of technological achievements of universities in actual production and application; up to now, we have formed trinity mechanism of innovative research, production application, and personnel training to promote production, education, research and application. Looking forward to the future, we are going to focus on the pharmaceutical fi